How to Get Evenity (Romosozumab) in Louisiana

Romosozumab: What It Is and Why Access Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, the drug both builds new bone and slows resorption. This dual mechanism sets it apart from every other osteoporosis therapy on the market.

The ARCH Trial Evidence

The ARCH trial (N=4,093) published in the New England Journal of Medicine compared romosozumab-to-alendronate sequencing against alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. At 24 months, the romosozumab-first group had a 48% lower risk of new vertebral fracture and a 27% lower risk of nonvertebral fracture compared to the alendronate-only group [1]. These results drove the FDA's April 2019 approval of Evenity for postmenopausal women at high risk for fracture [2].

Why Louisiana Patients Face Extra Hurdles

Access to romosozumab in Louisiana is shaped by three factors: Louisiana Medicaid does not cover the drug, the state's specialist density is lower than the national average in rural parishes, and the monthly injection schedule requires consistent clinical contact. For patients in Shreveport, Lake Charles, or Monroe, reaching a bone-health specialist can mean a two-hour drive each way. Telehealth eligibility and specialty pharmacy shipping help close that gap.

Who Can Prescribe Evenity in Louisiana

Louisiana law allows several provider types to prescribe romosozumab, but the clinical complexity of the drug and its black box cardiovascular warning mean that most prescriptions originate from a narrow set of specialists.

Physician Specialists (MD/DO)

Endocrinologists and rheumatologists write the majority of romosozumab prescriptions nationwide. In Louisiana, board-certified endocrinologists practice primarily in New Orleans, Baton Rouge, and Shreveport. Rheumatologists and orthopedic specialists who manage osteoporosis can also prescribe. Any licensed MD or DO in Louisiana may legally prescribe Evenity, though insurers often require the prescriber to document specialty credentials during prior authorization.

Nurse Practitioners and Physician Assistants

Louisiana grants full practice authority to NPs after completing a supervised transition period, meaning experienced NPs can independently prescribe romosozumab without physician co-signature [3]. PAs in Louisiana prescribe under a collaborative practice agreement with a supervising physician. Both provider types can initiate Evenity, but the prior authorization process may require supporting documentation from an endocrinologist or rheumatologist if the PA or NP does not hold a bone-health specialty credential.

Telehealth Prescribers

Louisiana permits telehealth prescribing for romosozumab. Providers licensed in the state can evaluate patients via synchronous video, order labs, and transmit prescriptions to specialty pharmacies. The Louisiana State Board of Medical Examiners requires that telehealth encounters meet the same standard-of-care benchmarks as in-person visits, including a documented history, review of imaging, and cardiovascular risk screening before initiating romosozumab.

Required Labs and Screening Before Starting Evenity

No prescriber should write for romosozumab without a defined set of baseline labs. The drug's black box warning for major adverse cardiovascular events (MACE) makes pre-treatment screening non-negotiable.

Bone and Metabolic Labs

Standard pre-treatment labs include serum calcium, 25-hydroxyvitamin D, and a comprehensive metabolic panel. Hypocalcemia must be corrected before the first dose. The Endocrine Society's 2020 clinical practice guideline recommends confirming vitamin D levels above 20 ng/mL and supplementing if deficient [4]. A baseline DXA scan within the prior 24 months is required for both clinical decision-making and insurance prior authorization.

Cardiovascular Risk Assessment

The FDA label includes a boxed warning: romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death [2]. Prescribers must document that the patient has not had a myocardial infarction or stroke within the preceding 12 months. Most insurers require a written cardiovascular risk statement from the prescriber as part of the prior authorization packet. A recent lipid panel, blood pressure documentation, and cardiac history review are standard.

What Labs Insurers Want to See

Commercial plans in Louisiana typically require documentation of: a T-score of -2.5 or lower at the hip or spine, or a history of fragility fracture, failure of or intolerance to at least one prior osteoporosis therapy (usually a bisphosphonate), and confirmation of no recent MACE. Some plans also require a FRAX score above the National Osteoporosis Foundation intervention threshold.

Prior Authorization in Louisiana: Step by Step

Almost every insurer covering romosozumab in Louisiana requires prior authorization. The process adds 5 to 21 business days to the prescribing timeline, depending on the plan.

Documentation Checklist

A complete prior authorization submission for Evenity in Louisiana typically includes:

• DXA scan results showing a T-score of -2.5 or below (hip or lumbar spine)
• Documentation of prior fragility fracture or FRAX score above intervention threshold
• Record of prior bisphosphonate trial (dates, duration, reason for discontinuation or failure)
• Cardiovascular clearance note (no MI or stroke in past 12 months)
• Baseline serum calcium and vitamin D levels
• Prescriber's specialty credentials
• Signed statement of medical necessity

Common Denial Reasons and Appeals

The most frequent denial reasons are missing documentation of prior bisphosphonate failure, absent cardiovascular clearance, and incomplete DXA reporting. If denied, Louisiana patients have the right to appeal. Internal appeals typically take 15 to 30 days. External review through the Louisiana Department of Insurance is available after internal appeal exhaustion. According to the American College of Rheumatology's 2022 guideline update, romosozumab is recommended as first-line therapy for patients at very high fracture risk, which can support appeal arguments when step therapy is the denial basis [5].

Louisiana Medicaid: Not Covered

Louisiana Medicaid does not cover romosozumab. Patients on Medicaid who meet clinical criteria have limited options: apply for Amgen's patient assistance program (Amgen Safety Net Foundation), explore clinical trial enrollment, or pursue a Medicaid exception request through their managed care organization. Exception requests require a letter of medical necessity from a specialist and are approved on a case-by-case basis.

Pharmacy Access and Dispensing in Louisiana

Romosozumab is a biologic administered as two subcutaneous injections (each 105 mg) per dose, delivered via prefilled syringes. This creates specific pharmacy and administration requirements.

Specialty Pharmacy Distribution

Most patients receive Evenity through a specialty pharmacy that ships directly to the prescriber's office or an infusion center. Amgen's distribution network includes national specialty pharmacies (Accredo, CVS Specialty, Optum Specialty) that ship to Louisiana addresses. The drug requires refrigeration at 2°C to 8°C and arrives in insulated packaging with cold-chain tracking.

503A Compounding Pharmacies

Louisiana licenses 503A compounding pharmacies, but romosozumab is a patented biologic monoclonal antibody. It cannot be compounded. No 503A pharmacy can legally produce a romosozumab equivalent. Patients searching for compounded alternatives should be aware that no biosimilar for romosozumab exists as of May 2026. The 503A pathway applies to other osteoporosis-related compounds (such as compounded calcium or vitamin D formulations) but not to Evenity itself.

Administration Settings

Because Evenity is a subcutaneous injection (not IV), it can be administered in a physician's office, a nurse-run clinic, or by the patient at home after training. Many Louisiana endocrinology and rheumatology offices administer the injection on-site during the monthly visit. Home self-injection is an option for patients who receive training from a healthcare provider and demonstrate competency with the prefilled syringe system.

Cost and Financial Assistance

Evenity's wholesale acquisition cost is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course. Out-of-pocket costs vary widely based on insurance status.

Commercial Insurance

Patients with commercial insurance and an approved prior authorization typically pay a copay or coinsurance. Amgen offers the Evenity copay card for eligible commercially insured patients, reducing out-of-pocket costs to as low as $5 per month. The copay program has an annual maximum benefit, usually capped between $12,000 and $15,000 per year.

Medicare Part B

Romosozumab administered in a physician's office is covered under Medicare Part B as a physician-administered drug. Medicare beneficiaries are responsible for 20% coinsurance after meeting the Part B deductible. For a $1,825 dose, the coinsurance is approximately $365 per injection. Medicare Supplement (Medigap) plans may cover some or all of this coinsurance.

Uninsured and Medicaid Patients

Amgen's Safety Net Foundation provides Evenity at no cost to patients who meet income eligibility requirements (generally at or below 300% of the federal poverty level). Application requires proof of income, a valid prescription, and documentation that the patient lacks adequate coverage. Processing takes 2 to 4 weeks.

Telehealth Pathways for Louisiana Residents

Telehealth offers a practical route for Louisiana residents in underserved parishes where bone-health specialists are scarce.

How Telehealth Visits Work for Evenity

A telehealth consultation for romosozumab typically follows this sequence: the provider reviews prior DXA scans and lab work uploaded to the patient portal, conducts a synchronous video evaluation, assesses cardiovascular risk factors, and if appropriate, submits the prescription and prior authorization electronically. Lab orders are sent to a local draw site (Quest, Labcorp, or a hospital lab). The prescription routes to a specialty pharmacy for home delivery or to the patient's local provider for in-office administration.

Limitations of Telehealth for This Drug

Telehealth cannot replace the initial DXA scan, which requires an in-person imaging appointment. Patients who choose home self-injection after telehealth initiation should receive hands-on injection training at least once, either from a local provider or through a specialty pharmacy nurse educator visit. Louisiana law does not restrict the number of telehealth-prescribed refills for romosozumab, but insurers may require an in-person visit at the 6-month mark for continued authorization.

Transferring a Prescription to Louisiana

Patients relocating to Louisiana or splitting time between states can transfer an active romosozumab prescription. Louisiana accepts prescription transfers from all 50 states for non-controlled substances. Romosozumab is not a controlled substance.

Transfer Process

The receiving Louisiana pharmacy contacts the dispensing pharmacy in the originating state to verify the prescription, remaining refills, and prescriber information. For specialty pharmacy transfers, the process may also involve re-running prior authorization with the patient's Louisiana-based insurer. If the patient's insurance plan changes with the move, a new prior authorization is typically required.

A new prescriber in Louisiana can also write a fresh prescription based on transferred medical records (DXA scans, lab results, cardiovascular clearance, treatment history). This is often faster than waiting for a pharmacy-to-pharmacy transfer through the specialty distribution network.

Timeline: From First Visit to First Injection

The total time from initial provider consultation to receiving the first romosozumab injection in Louisiana ranges from 2 to 6 weeks, depending on insurance type and prior authorization speed.

• Week 1: Initial consultation (telehealth or in-person), lab orders placed
• Week 1-2: Labs drawn and results reviewed; DXA scan if not completed in prior 24 months
• Week 2-3: Prior authorization submitted with complete documentation
• Week 3-5: Prior authorization decision (average 7-14 business days for commercial plans)
• Week 4-6: Specialty pharmacy ships Evenity; first injection administered

Patients with Medicare Part B and a willing administering physician may start sooner, as Part B "buy and bill" prior authorization is sometimes faster than specialty pharmacy benefit authorization.

The AACE 2020 clinical practice guideline emphasizes that delays in starting anabolic therapy for very-high-risk patients increase imminent fracture risk, which can support urgent prior authorization requests [6].